• Molecular NameBalsalazide
  • SynonymBalsalazida [Spanish]; balsalazide; Balsalazide disodium; Balsalazido [Spanish]; Balsalazidum [Latin]
  • Weight357.322
  • Drugbank_IDDB01014
  • ACS_NO80573-04-2
  • Show 3D model
  • LogP (experiment)2.417
  • LogP (predicted, AB/LogP v2.0)0.84
  • pkaN/A
  • LogD (pH=7, predicted)-4.11
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.45
  • LogSw (predicted, AB/LogsW2.0)2.13
  • Sw (mg/ml) (predicted, ACD/Labs)3.4
  • No.of HBond Donors4
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds7
  • TPSA145.16
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-inflammatory drug used in the treatment of inflammatory bowel disease.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding99.0
  • Volume of distribution (VD)4.5 L/h
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmBalsalazide is metabolised in the colon, by bacterial azoreductases, to 5-aminosalicyclic acid (5-ASA) which is responsible for the anti-inflammatory action, and 4-aminobenzoyl-β-alanine (4-ABA), an inert carrier. 25% of the released 5-ASA is inactivated in the colonic mucosa and liver to the N-acetylated metabolite, NASA. Likewise, 4-ABA becomes converted to its N-acetylated metabolite, NABA.
  • Half lifeElimination half-life of NASA is 6 to 9 h, and of 5-ASA is approx. 1 h
  • ExcretionIt is only NASA and NABA which are detected in urine; the parent drug is excreted mainly in faeces.
  • Urinary ExcretionN/A
  • Clerance4.5 L/h.
  • ToxicityHypersensitivity reaction: a 59-year-old woman was administered with 2.25 g balsalazide 3 times a day and after 8 days, was admitted into hospital with central chest pain, shortness of breath and back pain, which worsened over the next 3 days. Examination showed a pyrexial, splinter haemorrhages in her fingernails, raised jugular venous pressure, a loud pericardial rub and a soft, tender liver. Balsalazide treatment was stopped and all symptoms were resolved within a month. [V. Adhiyaman et al.,BMJ,2000, 320, 613].
  • LD50 (rat)N/A
  • LD50 (mouse)N/A